Clay B Siegall

Director Clay B Siegall purchases 62,500 STTK shares at $4.00 amid -82.5% annual revenue decline and $-14.8M net loss

Clay B Siegall, a Director, acquired 62,500 shares at $4.00 on 2026-06-09 for $250,000.00, increasing his holdings from 256.1K to 318.6K shares (+24.4%). The timing occurs within a severely stressed context: the company reported $0.00 revenue in its latest quarter, generated $-14.8M net income over its most recent full fiscal year, and experienced -82.5% annual revenue growth. The stock has declined -36.9% over 30 days and -30.2% over 90 days from the current price of $4.18, sitting -49.8% below its 52-week high of $8.33. While Siegall's cross-ticker track record shows 11 prior buys averaging +10.2% 30-day returns with a 60.00% 90-day win rate, this current acquisition occurs amid clear fundamental deterioration and sharp price weakness that distinguishes it from his historical buy pattern context. The size of the purchase—representing a material 24.4% increase in his direct holdings—reflects a substantial personal commitment at depressed price levels during a period of operational distress.

CEO Siegall purchases 25,450 shares of IMNM at $19.67 for $500.6K; stock now at $21.87, 3 of 5 prior buys well-timed at 90 days.

SIEGALL CLAY B, President and CEO, purchased 25,450 shares at $19.67 on 2026-03-27, increasing holdings from 665.3K to 690.7K shares (+3.8%). The current price of $21.87 represents a gain of approximately 11% from the transaction price. Examining his same-ticker history at IMNM reveals a mixed but notable pattern: of his 5 prior purchases, 3 demonstrated positive 90-day returns (2025-03-26 at +22.4%, 2025-01-31 at +14.3%, and 2025-12-19 at +1.7%), indicating timing acumen in roughly 60% of prior trades. However, the company's fundamentals present a stark counterpoint—the latest quarter showed revenue of $0.00 with a net loss of $-57.5M, annual revenue declined 23.2%, and the company remains unprofitable. The timing pattern of his prior buys at this ticker suggests selective execution, but the severe operational deterioration raises a material disconnect between insider buying activity and underlying business health.

CEO Clay Siegall bought 4,729 shares of IMNM at $21.15; stock up +15.0% in 30 days, +86.8% in 90 days.

CEO Clay Siegall purchased 4,729 shares at $21.15 on 2025-12-30, increasing his holdings to 665,254 shares. The timing follows a strong 90-day rally (+86.8%), with the stock currently at $21.18, near its 52-week high of $23.48. His prior three purchases at IMNM demonstrated favorable 90-day outcomes (+22.4%, +14.3%, +3.4%), and he was buying again within days of prior acquisitions on 2025-12-19 and 2025-12-18. However, Immunome is severely unprofitable ($-57.5M net income), generated zero revenue in the latest quarter, and posted -35.5% annual revenue growth, raising questions about the company's operational foundation. The convergence of strong stock momentum, repeated purchases within a narrow timeframe, and deteriorating fundamentals warrants scrutiny of whether this represents accumulated conviction or reflects price momentum unmoored from financial reality.

CEO Clay Siegall buys 7,278 shares of IMNM at $20.48; stock up 18.9% in 30 days, 108.6% in 90 days despite $-57.5M net income.

CEO Clay Siegall purchased 7,278 shares at $20.48 on 2025-12-19, bringing his total holdings to 660,525 shares. This follows a consecutive buy on 2025-12-18, suggesting sustained accumulation. Across his prior five trades at IMNM, four of four measurable transactions showed positive 90-day returns, with outcomes ranging from +3.4% to +22.4%, indicating a pattern of well-timed entry points at this ticker. The stock has appreciated 18.9% in the past 30 days and 108.6% over 90 days, tracking well above the CEO's cross-ticker buy average of +8.4% (30d) and +7.5% (90d). However, IMNM remains fundamentally challenged: the company recorded $-57,457,000.00 in net income and $0.00 in latest quarterly revenue, with annual revenue declining 35.5% year-over-year. The CEO's accumulation amid deteriorating financial metrics and revenue collapse warrants scrutiny of whether the recent price surge reflects speculative momentum or a turning point not yet visible in earnings.

CEO Siegall Clay B purchased 46,511 shares of IMNM at $21.50 for ~$1.0M on 2025-12-18; stock now at $19.95, -15.0% from 52-week high.

SIEGALL CLAY B, President and CEO, purchased 46,511 shares at $21.50 on 2025-12-18, increasing his holdings to 853,247 shares (+5.8% vs pre-transaction holdings). His five prior open-market purchases at Immunome showed a 90d win rate of 100% (all five prior buys had positive 90d returns), indicating consistent timing accuracy at this ticker. However, the fundamental context is notably challenging: the company reported revenue of $0.00 in its latest quarter, a net loss of $57,457,000.00, and annual revenue declined -35.5% year-over-year. The stock has since retreated -15.0% from its 52-week high despite a strong 90-day gain of +112.5% at the time of purchase. This executive's sustained accumulation pattern (his sixth buy at IMNM) suggests confidence in the recovery trajectory, yet occurs amid severe top-line contraction and persistent unprofitability.

CEO Clay Siegall buys 137,100 shares of IMNM at $7.29 (+20.5% to holdings) as stock down 72.2% from 52-week high; cluster buy pattern with 2 other insiders in 14 days

Clay Siegall, President and CEO, purchased 137,100 shares at $7.29 on 2025-03-26, increasing his holdings from 669,636 to 806,736 shares—a 20.5% net addition. This purchase occurs in a heavily depressed context: the stock trades at $7.09 today, down 72.2% from its 52-week high of $25.52 and down 24.2% over the past 30 days. At IMNM specifically, Siegall's prior 5 trades show mixed short-term outcomes (30d returns ranged from -8.7% to +21.3%), though 3 of 4 measurable 90-day outcomes were positive, suggesting his timing has historically favored multi-month windows. The timing signal here is complicated by the company's financial distress: revenue declined 35.5% year-over-year to $2.9M quarterly, and full-year net income was negative at -$47.1M. The purchase is part of a cluster pattern—2 other insiders also bought within the past 14 days—which may indicate coordinated confidence or a routine rebalancing cycle. Without FLAGS indicating a 10b5-1 trading plan, the discretionary nature of this buy during a steep drawdown warrants attention to whether the CEO's conviction extends to the company's turnaround narrative or reflects an opportunistic entry point.

CEO Siegall bought 150,000 shares at $7.75, raising stake to 669.6K; stock down -20.4% in 90 days at unprofitable $644.1M market-cap biotech.

SIEGALL CLAY B purchased 150,000 shares at $7.75 on 2025-01-31, expanding his holdings from 519.6K to 669.6K shares (+28.9%). The purchase occurred at a price substantially below the 52-week high of $27.34, with the stock currently trading at $10.32 after a -20.4% decline over the past 90 days. At same-ticker IMNM, his prior two buys in November 2024 posted strong 30-day returns (+12.2% and +15.0%), but his longer-dated record is mixed: one of five prior trades achieved positive 90-day outcomes. The company remains unprofitable with a net loss of $47.1M against quarterly revenue of $2.9M, and the CEO's accumulation occurs within a broader context of material stock decline and operational losses.

CEO Clay Siegall bought 100,000 shares ($962.2K) at IMNM over 2 days; stock down 59.2% from 52-week high, unprofitable.

Immunome's President and CEO Clay Siegall executed 2 separate purchases totaling 100,000 shares (100.0K shares) for $962,181.46 ($962.2K) between 2024-11-21 and 2024-11-22, raising his holdings from 419,636 to 519,636 shares (+23.8%). The blended purchase price was $9.62, whereas the current price is $11.15—already above his transaction price, but the stock remains -59.2% from its 52-week high and -25.5% over the past 90 days. The company is unprofitable with a net loss of $47,100,000.00 in its latest full year and generated only $2,910,000.00 in revenue last quarter. Notably, this transaction coincides with a cluster pattern: 2 other insiders also bought within the past 14 days. His prior trades at this ticker show mixed timing results (1 of 2 prior measurable buys was well-timed at the 90-day mark, with outcomes ranging from -8.7% to +3.8% at 30 days). The magnitude and timing of this concentrated purchase—combined with synchronized buying by other insiders—warrant close observation given the severe recent price deterioration and the company's loss position.